Ibrutinib(CAS: 936563-96-1)

Ibrutinib, with the CAS number 936563-96-1, is a selective inhibitor of Bruton's tyrosine kinase (BTK). It is a white to off-white solid with a molecular formula of C18H18N4O4S and is commonly used in the treatment of certain cancers, particularly B-cell malignancies. Its chemical structure features a pyrazole ring and a sulfonamide group, contributing to its pharmacological activity.

Ibrutinib (CAS: 936563-96-1) is primarily used in oncology to treat conditions such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia. It is also prescribed for autoimmune diseases like multiple myeloma and is widely researched for its potential in other therapeutic areas. Its role as a BTK inhibitor makes it significant in targeted cancer therapy.

Ibrutinib (CAS: 936563-96-1) is generally considered safe when used as directed, but it can have side effects such as gastrointestinal issues, fatigue, and bleeding. It is important to follow medical guidelines and handle it with appropriate care. Safety standards for Ibrutinib are well-established, and it is approved by regulatory agencies for specific therapeutic uses.

Ibrutinib (CAS: 936563-96-1) should be stored in a cool, dry place away from direct light. It is typically kept at a temperature between 15°C to 30°C (59°F to 86°F) and should be protected from moisture. Proper storage ensures its stability and potency, and it should be kept in a tightly sealed container.